Nazaj na portal Europarl

Choisissez la langue de votre document :

Ta dokument ni na voljo v vašem jeziku, zato v vrstici z jeziki izberite drugega.

Postopek : 2006/2591(RSP)
Potek postopka na zasedanju
Potek postopka za dokument : B6-0375/2006

Predložena besedila :


Razprave :

PV 05/07/2006 - 17
CRE 05/07/2006 - 17

Glasovanja :

PV 06/07/2006 - 6.19
CRE 06/07/2006 - 6.19
Obrazložitev glasovanja

Sprejeta besedila :


PDF 100kWORD 55k
PE 374.689v01-00
to wind up the debate on the statement by the Commission
pursuant to Rule 103(2) of the Rules of Procedure
by Luisa Morgantini, Feleknas Uca, Vittorio Agnoletto, Eva-Britt Svensson and Adamos Adamou
on behalf of the GUE/NGL Group
on HIV/AIDS: Time to Deliver

European Parliament resolution on HIV/AIDS: Time to Deliver 

The European Parliament,

–  having regard to the United Nations General Assembly Special Session (UNGASS) High-Level Meeting on HIV/AIDS of 2 June 2006 and the political declaration adopted at that meeting,

–  having regard to the UN Declaration of Commitment on HIV/AIDS, 'Global Crisis – Global Action', adopted by the United Nations General Assembly on 27 June 2001, during the 26th Special Session of the General Assembly,

–  having regard to the United Nations position paper on 'Preventing the Transmission of HIV among Drug Abusers',

–  having regard to the forthcoming International Conference on 'HIV/AIDS: Time to Deliver', to be held in Toronto in August 2006,

–  having regard to the Millennium Development Goals,

–  having regard to Rule 103(2) of its Rules of Procedure,

A.  whereas realization of human rights and fundamental freedoms for all is essential to reduce vulnerability to HIV/AIDS,

B.  whereas discrimination and stigmatization of people living with HIV/AIDS obstructs proper care and services,

C.  whereas more than 65 million people in the world have been infected with HIV, more than 25 million people have died, 15 million children have been orphaned by AIDS, and, of the 40 million people currently living with HIV, over 95% live in the developing world, with over 70% in Sub-Saharan Africa alone,

D.  whereas women now represent half of all people living with AIDS and 60% of those living with AIDS in Africa, with women being between two and four times as susceptible to catching the disease as men,

E.  whereas over half of all new HIV infections affect young people under the age of 25,

F.  whereas the term 'vulnerable populations' includes women and girls, young people, older people, the homosexual community, drug users, prostitutes, people living in poverty, prisoners, people in conflict and post-conflict situations, refugees and internally displaced persons, as well as HIV/AIDS outreach workers and people living with HIV/AIDS,

G.  whereas more than two million children are affected in Africa, but there is no way to diagnose a child before he reaches 18 months of age, and half of them die,

H.  whereas, as underlined in the last UNAIDS/WHO report 'AIDS Epidemic Update – December 2005', the development of new tools such as micro biocides needs to be supported in order to provide additional options for the response and should become part of comprehensive prevention strategies,

I.  whereas many organisations close to the UNGASS session reported that the political and economic interests of negotiating countries and blocs were influenced by the political and economic interests of some countries, reputedly weakening the financial commitments made to combating the disease,

J.  whereas the Doha Declaration placed the protection of public health above the protection of private commercial interests and confirmed the right of developing countries to use TRIPS Agreement safeguards, such as compulsory licences, to overcome patents when necessary in order to protect public health and promote access to medicines for all,

K.  whereas the debt burden, the structural adjustment programmes and the current pressure to liberalise services are reducing the capacity of many developing countries to provide basic services (water supply, health, education) to all their population, which is essential to reduce the impact of diseases,

L.  whereas the current pricing system based on companies giving voluntary discounts on medicines to developing countries does not guarantee the affordability of medicines, with some single-source drugs being too expensive even with a discount; some discounts not being available because manufacturers have not registered or are not marketing their drugs in certain countries, and some companies not offering discounts at all to middle-income countries,

1.  Welcomes the declaration of the UNGASS Special Session of 2 June 2006, in particular its references to vulnerable groups, its focus on women, girls and young people, the growing feminisation of AIDS, the role that gender inequalities and violence against women play in increasing vulnerability to HIV/AIDS and the extension of the definition of universal access to comprehensive prevention programmes, treatment, care and support;

2.  Regrets, nevertheless, the fact that international HIV/AIDS targets have thus far not been met, and the lack of firm commitment on where the extra $ 20-23 billion which is needed by 2010 will come from;

3.  Calls on the international community to deliver on its promises during the Toronto Conference in August, and calls on the Commission and the Member States to ensure that health spending in developing countries reaches levels commensurate with the political commitments made, both in terms of the Millennium Development Goals in general and combating HIV/AIDS in particular;

4.  Criticises the Commission for not taking into account the European Parliament's resolution on

5.  Underlines that, in order to effectively halt and reverse the spread of HIV/AIDS, there must be universal acknowledgement of those groups most vulnerable to the disease, in order that appropriate preventive measures can be taken to halt the spread of the infection, including the involvement of HIV-positive girls and women in the development and implementation of programmes and the involvement of men in sexual health and rights;

6.  Emphasises that prevention strategies need to recognise the reality that many women and girls do not have control over their own sexuality, and that through successful integration of sexual and reproductive health rights and services and HIV/AIDS initiatives a greater number of girls and women could receive a wider range of more adequate services and information, and urges the Commission and partner countries to prioritise broad prevention strategies in Country Strategy Papers, including programmes promoting the use of condoms and HIV/AIDS education geared towards young people;

7.  Calls on national governments and local authorities to provide a supportive environment for orphans and girls and boys infected and affected by HIV/AIDS, including by providing appropriate counselling and psycho-social support and ensuring their enrolment in school and access to shelter, good nutrition, health and social services on an equal basis with other children;

8.  Criticises the contradictions highlighted by the Commission's appalling track record in development fund spending in the healthcare sector; underlines, for example, that in 2003 only 5.2% of the EDF was earmarked for health spending and only 4% in 2002, and deplores the fact that the Commission intends to propose that only 6% of development funds within the new development cooperation instrument be allocated to human and social development, covering not only healthcare, HIV/AIDS, sexual and reproductive health, but all other aspects of social development, including children, education and gender programmes;

9.  Calls on the Commission to drastically increase its budget for healthcare in developing countries, to increase to € 1 million its contribution to the Global Fund against HIV/AIDS, malaria and TB, and to aim for at least 50% of all ODA to be spent on achieving the Millennium Development Goals;

10  Calls on the Commission to allow for large increases in sectoral budgetary support to health sectors, particularly to retain key health workers in developing countries;

11.  Notes that 1 January 2005 saw the implementation of the WTO's agreement on TRIPS in India, compelling India to recognise product patents on medicines; notes that the presence on the market of several producers has brought down the prices of first-line AIDS drugs from US$ 10 000 to US$ 150 per patient per year over the past five years; notes with concern that newer drugs, and particularly more expensive second-line treatments, must not only be produced by patent holders that could set a monopoly price unaffordable for developing countries;

12.  Criticises bilateral and regional trade agreements that include provisions which go beyond the WTO's TRIPS Agreement ('TRIPS-plus') in order to restrict, if not eliminate, the safeguards established by the Doha Declaration to ensure the primacy of health over commercial interests; points out the responsibility of those countries, in particular the United States, that put pressure on developing countries to sign such free-trade agreements;

13.  Criticises the fact that the WTO Hong Kong Declaration did not benefit the supply of HIV/AIDS drugs to developing countries;

14.  Underlines that compulsory licensing and differential prices have not solved the problem, and calls on the Commission to propose new solutions to ensure genuine access to HIV/AIDS treatments at affordable prices;

15.  Points out that fixed-dose combinations (pills containing two or three AIDS drugs in one tablet) simplify the treatment of HIV/AIDS and must be prioritised in areas where there are few hospitals or healthcare workers;

16.  Instructs its President to forward this resolution to the Council, the Commission, the Member States, the UN Secretary-General and the World Health Organisation.

Pravno obvestilo - Varstvo osebnih podatkov